ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 366 participants.
Also called NCT07737964
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 366 participants
- Registry
-
NCT07737964 -
2025-524344-35-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07737964. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
- Acronym
- ACHIEVE
- Condition
- Heart Failure
- Intervention (Drug)
- Acetazolamide
- Intervention (Drug)
- Furosemide
- Lead sponsor
- University Hospital, Montpellier
Record details
- Record id
cardio:ct-nct07737964- Content hash
a8578ea25558e02edb030b0641e31da824f504073b4fa580afd71361fe63a538